AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American S
Go back to AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American S| AbbVie (NYSE: ABBV) | Delayed: 266.64 +2.16 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.48 | 52 Week High | $68.12 | |||
| Open | $263.10 | 52 Week Low | $50.71 | |||
| Day High | $266.73 | P/E | 57.84 | |||
| Day Low | $262.15 | EPS | $4.61 | |||
| Volume | 631,471 | |||||
